Nirvana Life Sciences Inc. Announces the appointment of Andrew Samann to Advisory Board
VANCOUVER, BC, April 5, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE : NIRV), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Andrew Samann to the Company’s Advisory Board.
Andrew Samann is CEO and Principal Consultant of Orion GMP Solutions, a Pharmaceutical Process Engineering firm founded in 2015. Andrew’s background is firmly rooted in Quality Management Systems (QMS) and Good Manufacturing Practices (GMP), with a track record of serving more than 150 clients globally.
Andrew prioritizes early expertise advantage, diversified scientific partnerships, group collaboration and execution excellence. Through his career he has maintained a position at the forefront of the industry as well as building an immense network of contacts. Andrew earned his Bachelor of Science in Biochemistry from the University of Michigan and has written multiple peer reviewed scientific publications related to protein chemistry. Following a tour of military service, he began his career with Cayman Chemicals as a GMP QC Chemist. He has since served on the Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) as GMP lead Auditor.
Mr. Samann commented, “Working with the team at Nirvana Life Sciences is one of the most impactful projects I’ve worked on to date. I’m excited to see this novel opportunity and industry continue to blossom.”
Mr. Bruce Clark, Chief Executive Officer of Nirvana commented, “We continue to advance our project, and are pleased that Andrew Samann has chosen to join our team. The expertise he brings in Quality Management as well as Pharmaceutical Process Engineering will be a tremendous asset to every stage of our development.”About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana’s team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.Forward Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward- looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
SOURCE Nirvana Life Sciences Inc.
For further information: Bruce Clark, CEO, info@nirvanalifescience.com, Phone: 604-401-8100